AACC uses Cookies to ensure the best website experience. Continuing without changing Cookie settings assumes you consent to our use of cookies on this device. You can change these settings at any time, but that may impair functionality on our websites. Review our cookie and privacy policy

Optimizing LC-MS/MS for the TDM of Immunosuppressants - CD

This webcast originally aired as a live webinar
sponsored by AACC and supported by a grant from Waters Corporation on May 14,
2013. More labs are bringing tandem mass spectrometry platforms in house to
serve the needs of their hospitals and health systems that perform transplants
or monitor transplant patients on immunosuppressant drugs. Health care
organizations are also turning to LC-MS/MS as a viable alternative to
immunoassay platforms for the analysis of immunosuppressant concentrations in
transplant patients. View this program and learn about the advantages and
disadvantages of using LC-MS/MS versus immunoassay for clinical measurement of
immunosuppressants; hear information on standardization efforts related to mass
spec-based assays for immunosuppressants such as cyclosporine, tacrolimus, and
rapamycin; and understand the current thinking on monitoring newer drugs such as
everolimus using LC-MS/MS.